We are live on ! Find out more
SCM

Squadron Capital Management Portfolio holdings

AUM $322M
This Fund
S&P 500
This Quarter Est. Return
+34.37%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$322M
AUM Growth
+$49.3M
Cap. Flow
+$2.89M
Cap. Flow %
0.9%
Top 10 Hldgs %
66.2%
Holding
60
New
23
Increased
11
Reduced
7
Closed
17

Top Buys

Rank Stock Value
1
CCCC icon
C4 Therapeutics
CCCC
+$16.9M
2
IVA
Inventiva
IVA
+$9.13M
3
ELVN icon
Enliven Therapeutics
ELVN
+$6.79M
4
FBRX icon
Forte Biosciences
FBRX
+$5.34M
5
ADAG
Adagene
ADAG
+$4.7M

Top Sells

Rank Stock Value
1
KALV
KalVista Pharmaceuticals
KALV
+$19.8M
2
ABVX
Abivax
ABVX
+$14.5M
3
NKTR icon
Nektar Therapeutics
NKTR
+$8.99M
4
RLMD icon
Relmada Therapeutics
RLMD
+$7.86M
5
ANL
Adlai Nortye Group ADS
ANL
+$6.09M

Sector Composition

Rank Sector Weight
1 Healthcare 90.64%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RLMD icon
1
Relmada Therapeutics
RLMD
$489M
$50.9M 15.78%
7,350,000
-1,124,571
-13% -$7.86M
CCCC icon
2
C4 Therapeutics
CCCC
$504M
$33.6M 10.43%
7,200,000
+4,950,000
+220% +$16.9M
COGT icon
3
Cogent Biosciences
COGT
$6.29B
$33.5M 10.39%
865,000
+77,508
+10% +$2.71M
KOD icon
4
Kodiak Sciences
KOD
$2.34B
$19.5M 6.05%
500,000
+120,000
+32% +$4.67M
RLAY icon
5
Relay Therapeutics
RLAY
$4.33B
$18.1M 5.63%
970,000
+297,500
+44% +$4.32M
ZNTL icon
6
Zentalis Pharmaceuticals
ZNTL
$356M
$17.9M 5.57%
3,700,000
+69,000
+2% +$275K
EWTX icon
7
Edgewise Therapeutics
EWTX
$4.86B
$11.8M 3.66%
290,000
-60,000
-17% -$2.07M
MAZE
8
Maze Therapeutics
MAZE
$1.64B
$10M 3.1%
335,000
+77,500
+30% +$2.03M
IVA
9
Inventiva
IVA
$1.11B
$9.2M 2.86%
2,435,000
+1,900,000
+355% +$9.13M
ANL
10
Adlai Nortye Group ADS
ANL
$912M
$8.8M 2.73%
764,876
-500,355
-40% -$6.09M
ELVN icon
11
Enliven Therapeutics
ELVN
$4.48B
$8.12M 2.52%
+160,000
New +$6.79M
AVBP icon
12
CALL
ArriVent BioPharma
AVBP
$1.39B
$6.36M 1.97%
183,000
+73,000
+66% +$2.15M
PALI icon
13
Palisade Bio
PALI
$350M
$6.27M 1.95%
3,000,000
– –
BIOA
14
CALL
BioAge Labs
BIOA
$431M
$6.13M 1.9%
+250,000
New +$4.52M
IKT icon
15
Inhibikase Therapeutics
IKT
$349M
$6.09M 1.89%
3,000,000
-500,000
-14% -$895K
ADAG
16
Adagene
ADAG
$258M
$5.25M 1.63%
+1,250,000
New +$4.7M
FBRX icon
17
Forte Biosciences
FBRX
$1.63B
$4.78M 1.48%
+225,000
New +$5.34M
RZLT icon
18
CALL
Rezolute
RZLT
$482M
$4.68M 1.45%
+900,000
New +$3.34M
IFRX icon
19
InflaRx
IFRX
$302M
$4.48M 1.39%
+2,000,000
New +$3.76M
ASMB icon
20
Assembly Biosciences
ASMB
$718M
$4.4M 1.36%
+160,000
New +$4.36M
CMPS
21
CALL
Compass Pathways
CMPS
$1.97B
$4.32M 1.34%
+305,000
New +$3.1M
PMN icon
22
ProMIS Neurosciences
PMN
$133M
$4.28M 1.33%
324,977
– –
CTNM
23
Contineum Therapeutics
CTNM
$626M
$4.26M 1.32%
+260,000
New +$3.41M
CMPS
24
Compass Pathways
CMPS
$1.97B
$4.25M 1.32%
+300,000
New +$3.04M
DFTX
25
Definium Therapeutics
DFTX
$5.81B
$4M 1.24%
+85,000
New +$2.1M
1
2 3

Similar funds

SST
S Squared Technology New York $322M AUM 92.75% 1-Year Est. Return
CW
Curio Wealth Annapolis, Maryland $322M AUM 16.26% 1-Year Est. Return
WW
Westshore Wealth Newport Beach, California $322M AUM 24.46% 1-Year Est. Return
NAG
Northstar Advisory Group Northfield, New Jersey $322M AUM 36.79% 1-Year Est. Return
JGIA
Jackson Grant Investment Advisers Stamford, Connecticut $322M AUM 20.03% 1-Year Est. Return
EI
EnCap Investments Houston, Texas $322M AUM
KF
Ketron Financial Novato, California $322M AUM
QFPS
Quantum Financial Planning Services Spokane, Washington $323M AUM 14.02% 1-Year Est. Return

Squadron Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Squadron Capital Management held 60 positions worth $322M, up 18% from $273M the previous quarter. Its ten largest holdings account for 66% of the portfolio.

Squadron Capital Management's Q2 2026 filing shows 23 new, 11 increased, 7 reduced and 17 closed positions. Its largest new stake was Enliven Therapeutics: 160,000 shares worth $8.12M. The largest sale was KalVista Pharmaceuticals, an estimated $19.8M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, down from 92% a quarter earlier.

  • Squadron Capital Management's largest Q2 2026 buy was Enliven Therapeutics: 160,000 shares worth $8.12M.
  • Squadron Capital Management added most to C4 Therapeutics in Q2 2026, an estimated $16.9M increase.
  • Squadron Capital Management's biggest Q2 2026 reduction was Relmada Therapeutics, cutting an estimated $7.86M.
  • Squadron Capital Management fully exited KalVista Pharmaceuticals in Q2 2026, selling an estimated $19.8M.
  • Squadron Capital Management's ten largest holdings make up 66% of its $322M portfolio in Q2 2026.
  • Squadron Capital Management opened 23 new positions and closed 17 in Q2 2026.
  • Squadron Capital Management's portfolio value rose 18% quarter-over-quarter to $322M.

Based on Squadron Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.